881016-89-3

Basic information

• Product Name: A-BROMO-1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-PIPERIDINEACETIC ACID
• Synonyms: A-BROMO-1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-PIPERIDINEACETIC ACID;2-BroMo-2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid;2-bromo-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid;1-Boc-4-(bromo-carboxy-methyl)-piperidine
• CAS NO: 881016-89-3
• Molecular Formula: C12H20BrNO4
• Molecular Weight: 322.2
• Mol File: 881016-89-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: A-BROMO-1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-PIPERIDINEACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: A-BROMO-1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-PIPERIDINEACETIC ACID(881016-89-3)
• EPA Substance Registry System: A-BROMO-1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-PIPERIDINEACETIC ACID(881016-89-3)

Safety Data

• Hazardous Substances Data: 881016-89-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 175213-46-4 1-t-Butoxycarbonyl-4-(methoxycarbonylmethyl)piperidine 
• 168986-49-0 4-piperidine acetic acid methyl ester 
• 881016-88-2 4-(bromo-methoxycarbonyl-methyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists

A series of substituted dipiperidine compounds have been synthesized and identified as selective CCR2 antagonists. Combining the most favorable substituents led to the discovery of remarkably potent CCR2 antagonists displaying IC50 values in th

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Substituted dipiperidine CCR2 antagonists

Substituted dipiperidine compounds of Formula (I) or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.